StockDriftsStockDriftsTop 2 Catalys Pacific, LLC Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc. | 92.94% | 7.90M | $213.2M | +0.00%(+0) | $9.20(+192.44%) | 2026-06-30 | |
| PHAT | Phathom Pharmaceuticals, Inc. | 7.06% | 1.49M | $16.2M | +0.00%(+0) | $12.00(-28.22%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative | Since First Filing (10 quarters) |
|---|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — | +184.11% |
| Top 20 Holdings Unweighted | — | — | — | — | +161.21% |
Catalys Pacific, LLC reports $229.45M in US-listed equity holdings across 2 positions in its most recent 13F filing. Its largest disclosed positions are MLYS (92.9%) and PHAT (7.1%). The top 20 holdings account for 100% of reported assets. Its disclosed equity book has returned +184.11% cumulatively over 10 quarters. Figures reflect the Q2 2026 filing.
Sign up free to track Catalys Pacific, LLC, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Catalys Pacific, LLC’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 2011385). View Catalys Pacific, LLC’s 13F filings on SEC